Arrayit Corporation (ARYC) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arrayit Corporation (ARYC) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 58/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Arrayit Corporation (ARYC) Resumen de Asistencia Médica y Tuberías
Arrayit Corporation develops, manufactures, and markets life science tools and integrated systems for genetic variation analysis and diagnostics. The company's microarray technology and instruments serve genomic research centers, pharmaceutical companies, and academic institutions. With a focus on early disease detection, Arrayit operates in the competitive medical diagnostics and research sector.
Tesis de Inversión
Arrayit Corporation operates in the medical diagnostics and research sector, focusing on microarray technology. The company's gross margin of 49.4% indicates potential profitability in its core operations. However, the negative profit margin of -231.4% raises concerns about overall financial health. Key growth catalysts include expanding the application of its microarray technology in early disease detection and increasing sales of automated microarray instruments. Potential risks include the company's small market capitalization of $0.00B and high beta of -15.67, indicating high volatility. Investors should carefully consider the financial metrics and market position before investing.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Gross margin of 49.4% suggests potential efficiency in Arrayit's core microarray technology business.
- Negative profit margin of -231.4% raises concerns about the company's overall financial health and expense management.
- Market capitalization of $0.00B indicates the company is a micro-cap stock with associated volatility and liquidity risks.
- Beta of -15.67 suggests the stock price moves inversely and with greater magnitude than the market, indicating high volatility.
- Arrayit serves genomic research centers, pharmaceutical companies, and academic institutions, indicating a diversified customer base within the life sciences sector.
Fortalezas
- Proprietary microarray printing technology
- Integrated systems for genetic variation analysis
- Established relationships with research institutions
- Specialized expertise in microarray applications
Debilidades
- Negative profit margin
- Small market capitalization
- High beta indicating high volatility
- Limited financial resources
Catalizadores
- Ongoing: Expansion of microarray applications in early disease detection.
- Ongoing: Increasing sales of automated microarray instruments.
- Ongoing: Development and marketing of consumables for microarray technology.
- Ongoing: Entering strategic partnerships with pharmaceutical companies.
- Ongoing: Expanding into international markets.
Riesgos
- Potential: Competition from larger companies with greater resources.
- Potential: Regulatory changes affecting the medical diagnostics industry.
- Potential: Technological advancements rendering current products obsolete.
- Potential: Economic downturns impacting research funding.
- Ongoing: Negative profit margin and limited financial resources.
Oportunidades de crecimiento
- Expanding Microarray Applications in Early Disease Detection: Arrayit can capitalize on the growing demand for early disease detection by developing and marketing diagnostic microarrays for various treatable disease states. The market for early disease diagnostics is projected to reach billions of dollars by 2030, driven by advancements in genomics and proteomics. Arrayit's microarray technology offers a platform for high-throughput screening and personalized medicine, providing a competitive advantage in this expanding market. Timeline: Ongoing.
- Increasing Sales of Automated Microarray Instruments: Arrayit can increase revenue by expanding the sales of its automated microarray manufacturing instruments, such as NanoPrint and SpotBot Titan, to research institutions and pharmaceutical companies. The market for automated laboratory equipment is expected to grow, driven by the need for increased efficiency and throughput in research and development. Arrayit's instruments offer customizable solutions for microarray manufacturing, catering to the specific needs of its customers. Timeline: Ongoing.
- Developing and Marketing Consumables for Microarray Technology: Arrayit can leverage its existing customer base by developing and marketing consumables, such as glass substrates, reagents, and clean room supplies, for microarray technology. The market for laboratory consumables is stable and recurring, providing a consistent revenue stream for the company. By offering high-quality consumables specifically designed for its instruments, Arrayit can enhance customer loyalty and increase market share. Timeline: Ongoing.
- Entering Strategic Partnerships with Pharmaceutical Companies: Arrayit can accelerate its growth by entering strategic partnerships with pharmaceutical companies to develop and commercialize diagnostic microarrays and tools for specific disease areas. Collaborating with established pharmaceutical companies can provide access to funding, expertise, and distribution channels, enabling Arrayit to expand its market reach and product portfolio. These partnerships can focus on developing personalized medicine solutions and companion diagnostics. Timeline: Ongoing.
- Expanding into International Markets: Arrayit can expand its geographic reach by targeting international markets, particularly in Asia and Europe, where there is growing demand for life science tools and diagnostic technologies. Entering new markets requires adapting products and services to local regulatory requirements and customer needs. By establishing partnerships with local distributors and research institutions, Arrayit can effectively penetrate these markets and increase its global presence. Timeline: Ongoing.
Oportunidades
- Expanding microarray applications in early disease detection
- Increasing sales of automated microarray instruments
- Developing and marketing consumables
- Entering strategic partnerships with pharmaceutical companies
Amenazas
- Competition from larger companies
- Regulatory changes
- Technological advancements
- Economic downturns
Ventajas competitivas
- Proprietary microarray printing technology.
- Integrated systems for genetic variation analysis.
- Established relationships with research institutions and pharmaceutical companies.
- Specialized expertise in microarray technology and applications.
Acerca de ARYC
Arrayit Corporation, founded to advance life science research and diagnostics, develops, manufactures, and markets tools and integrated systems for analyzing genetic variation and biological function. The company's core business revolves around microarray technology, which enables the analysis of DNA, protein, antibody, lipid, and carbohydrate microarrays for applications such as gene expression, genotyping, and protein profiling. Arrayit offers a range of automated microarray manufacturing instruments, including the NanoPrint, SpotBot Titan, and SpotLight CCD fluorescence scanners. These instruments cater to various research and diagnostic needs, providing solutions for high-throughput sample processing and analysis. In addition to instruments, Arrayit manufactures consumables like glass substrates, reagents, and clean room supplies. The company serves genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies worldwide. Headquartered in Sunnyvale, California, Arrayit Corporation continues to focus on developing innovative tools for early disease detection and advancing life science research.
Qué hacen
- Develops microarray tools and components.
- Manufactures life science tools and integrated systems.
- Markets life science tools and integrated systems.
- Offers custom printing and analysis of microarrays for research.
- Identifies and develops diagnostic microarrays for early disease detection.
- Provides automated microarray manufacturing instruments.
Modelo de Negocio
- Sales of microarray tools and components to research institutions and pharmaceutical companies.
- Custom printing and analysis of microarrays for research purposes.
- Development and sales of diagnostic microarrays for early disease detection.
- Manufacturing and sales of automated microarray manufacturing instruments.
Contexto de la Industria
Arrayit Corporation operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market for microarray technology is driven by the need for high-throughput analysis of genetic variation and biological function. Arrayit competes with companies offering similar tools and services, including those specializing in genomics, proteomics, and diagnostics. The industry is subject to regulatory requirements and intellectual property protection, influencing the competitive landscape and market access.
Clientes Clave
- Genomic research centers
- Pharmaceutical companies
- Academic institutions
- Clinical research organizations
- Government agencies
- Biotechnology companies
Finanzas
Gráfico e información
Precio de la acción de Arrayit Corporation (ARYC): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 mar 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ARYC.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ARYC.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ARYC en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Rene A. Schena
Managing
Rene A. Schena is the managing person at Arrayit Corporation, overseeing the company's operations and strategic direction. Information about his detailed career history, education, and previous roles is not available in the provided data. He is responsible for leading the company's efforts in developing, manufacturing, and marketing life science tools and integrated systems.
Historial: Due to limited information, Rene A. Schena's specific achievements, strategic decisions, and company milestones under his leadership cannot be comprehensively assessed. However, as the managing person, he is responsible for guiding the company's activities in the competitive life sciences technology sector and managing its seven employees.
Información del mercado OTC de ARYC
The OTC Other tier represents the lowest tier of the OTC market, indicating that Arrayit Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor news and press releases for any updates or developments.
- Consult with a financial advisor before investing.
- Development of microarray tools and components.
- Manufacturing of life science tools and integrated systems.
- Marketing of life science tools and integrated systems.
Lo Que los Inversores Preguntan Sobre Arrayit Corporation (ARYC)
¿Cuáles son los factores clave para evaluar ARYC?
Arrayit Corporation (ARYC) actualmente tiene una puntuación IA de 58/100, indicando puntuación moderada. Fortaleza clave: Proprietary microarray printing technology. Riesgo principal a monitorear: Potential: Competition from larger companies with greater resources.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ARYC?
ARYC actualmente puntúa 58/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ARYC?
Los precios de ARYC se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ARYC?
La cobertura de analistas para ARYC incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ARYC?
Las categorías de riesgo para ARYC incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from larger companies with greater resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ARYC?
La relación P/E para ARYC compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ARYC sobrevalorada o infravalorada?
Determinar si Arrayit Corporation (ARYC) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ARYC?
Arrayit Corporation (ARYC) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available company data and may be limited due to OTC listing.
- AI analysis pending for ARYC.